340 related articles for article (PubMed ID: 10235152)
1. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.
Shipley WU; Thames HD; Sandler HM; Hanks GE; Zietman AL; Perez CA; Kuban DA; Hancock SL; Smith CD
JAMA; 1999 May; 281(17):1598-604. PubMed ID: 10235152
[TBL] [Abstract][Full Text] [Related]
2. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
3. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
Hung AY; Levy L; Kuban DA
Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
[TBL] [Abstract][Full Text] [Related]
4. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
Kuban DA; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):915-28. PubMed ID: 14575822
[TBL] [Abstract][Full Text] [Related]
5. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
6. Dose response in prostate cancer with 8-12 years' follow-up.
Hanks GE; Hanlon AL; Epstein B; Horwitz EM
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
[TBL] [Abstract][Full Text] [Related]
7. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
D'Amico AV; Renshaw AA; Sussman B; Chen MH
JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
11. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy.
Kestin LL; Vicini FA; Ziaja EL; Stromberg JS; Frazier RC; Martinez AA
Cancer; 1999 Oct; 86(8):1557-66. PubMed ID: 10526285
[TBL] [Abstract][Full Text] [Related]
12. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.
Zietman AL; Coen JJ; Shipley WU; Willett CG; Efird JT
J Urol; 1994 Mar; 151(3):640-5. PubMed ID: 7508522
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Lee WR; Hanlon AL; Hanks GE
J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
[TBL] [Abstract][Full Text] [Related]
14. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
Pollack A; Smith LG; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469
[TBL] [Abstract][Full Text] [Related]
15. Factors that influence biochemical failure after radiation therapy for stage T1c prostate cancer.
Mohideen MN; McCall AR; Feinstein J; Sidrys J; Bricker P; Luka S
Am J Clin Oncol; 1998 Feb; 21(1):6-11. PubMed ID: 9499260
[TBL] [Abstract][Full Text] [Related]
16. The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma.
Aref I; Eapen L; Agboola O; Cross P
Radiother Oncol; 1998 Aug; 48(2):203-7. PubMed ID: 9783893
[TBL] [Abstract][Full Text] [Related]
17. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
Lattanzi JP; Hanlon AL; Hanks GE
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):569-73. PubMed ID: 9231681
[TBL] [Abstract][Full Text] [Related]
18. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.
Thames H; Kuban D; Levy L; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):929-43. PubMed ID: 14575823
[TBL] [Abstract][Full Text] [Related]
19. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
[TBL] [Abstract][Full Text] [Related]
20. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Blank K; Broderick GA; Tomaszewski JE; Renshaw AA; Kaplan I; Beard CJ; Wein A
JAMA; 1998 Sep; 280(11):969-74. PubMed ID: 9749478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
